Patents Assigned to Johnson & Johnson Pharmaceutical Research and Development LLC
-
Publication number: 20100189654Abstract: A method for evaluating the effect of a compound on vasomotor response in vivo comprises the steps of administering said compound to a rabbit and measuring the diameter of the vessel lumen of a central ear artery of said rabbit in comparison with the baseline diameter of the vessel lumen of said central ear artery of said rabbit, said baseline diameter being measured prior to the administration of said compound.Type: ApplicationFiled: October 21, 2009Publication date: July 29, 2010Applicant: Johnson & Johnson Pharmaceutical Research & Development, LLCInventors: Tom Jay Parry, Bruce P. Damiano, Edward C. Giardino, Margery A. Connelly
-
Publication number: 20100136594Abstract: A method of screening a compound which modulates dipeptidyl peptidase I (DPPI) activities comprises the steps of adding a peptide substrate of DPPI to a reaction mixture which comprises DPPI and a compound, wherein the peptide substrate of DPPI has at least 3 amino acids and binds to a binding site of DPPI in addition to the S1-S2 site; and measuring the molecular weight of the substrate, wherein a change in the molecular weight of the substrate is indicative of the presence of DPPI activity.Type: ApplicationFiled: October 21, 2009Publication date: June 3, 2010Applicant: Johnson & Johnson Pharmaceutical Research & Development, LLCInventors: Matthew Olson, Matthew Todd
-
Patent number: 7655756Abstract: A method for the identification of novel compounds that interact and stabilize the ligand binding domain of estrogen-related receptor gamma (ERR?), a methodology for producing diffraction quality crystal structures in the presence of antagonist and agonist ligands, including Bisphenol A, and the identification of novel biologically-active compounds that have an effect on the transcriptional-activating activity of ERR? are disclosed.Type: GrantFiled: May 26, 2006Date of Patent: February 2, 2010Assignee: Johnson & Johnson Pharmaceutical Research & Development, LLCInventors: Marta C. Abad, Dionisios Rentzeperis, John O'Neill, Hossein B. Askari, Cynthia M. Milligan, Frank A. Lewandowski
-
Patent number: 7317025Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.Type: GrantFiled: September 24, 2004Date of Patent: January 8, 2008Assignee: Johnson & Johnson Pharmaceutical Research & Development, LLCInventors: Nicholas I. Carruthers, Wenying Chai, Scott L. Dax, Jill A. Jablonowski, Xiaobing Li, Timothy W. Lovenberg, William V. Murray, Dale A. Rudolph, Mark Seierstad, Mark A. Youngman
-
Patent number: 7112427Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.Type: GrantFiled: August 18, 2003Date of Patent: September 26, 2006Assignee: Johnson & Johnson Pharmaceutical Research and Development LLCInventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
-
Patent number: 6730480Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic application.Type: GrantFiled: January 24, 2002Date of Patent: May 4, 2004Assignee: Johnson & Johnson Pharmaceutical Research and Development LLCInventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas